The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Export 11032 results:
[ Author(Asc)] Title Type Year
Filters: Filter is   [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Polyzos, S. A., & Kountouras J. (2015).  Novel Advances in the Association Between Helicobacter pylori Infection, Metabolic Syndrome, and Related Morbidity.. Helicobacter. 20(6), 405-9.
Polyzos, S. A., Kountouras J., Mantzoros C. S., Polymerou V., & Katsinelos P. (2017).  Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial.. Diabetes Obes Metab. 19(12), 1805-1809.
Polyzos, S. A., Anastasilakis A. D., & Terpos E. (2009).  Paget's disease of bone: emphasis on treatment with zoledronic acid.. Expert Rev Endocrinol Metab. 4(5), 423-434.
Polyzos, S. A., & Mantzoros C. S. (2018).  Sixty-six years of Metabolism, Clinical and Experimental: The journey of a journal and opportunities and challenges looking ahead.. Metabolism. 78, A4-A9.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2016).  Adipokines in nonalcoholic fatty liver disease.. Metabolism. 65(8), 1062-79.
Polyzos, S. A., Goulas A., & Papaioannidou P. (2023).  Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis.. Curr Med Chem.
Polyzos, S. A., Kountouras J., Goulas A., & Duntas L. (2020).  Selenium and selenoprotein P in nonalcoholic fatty liver disease.. Hormones (Athens). 19(1), 61-72.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., & Terpos E. (2023).  Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease: Potential therapeutic implications.. Hepatobiliary Pancreat Dis Int.
Polyzos, S. A., & Kountouras J. (2012).  Visual vignette. Anaplastic thyroid carcinoma.. Endocr Pract. 18(1), 108.
Polyzos, S. A., & Kountouras J. (2016).  Homocysteine in nonalcoholic steatohepatitis: A reply.. Eur J Intern Med. 35, e40-e41.
Polyzos, S. A., Toulis K. A., Goulis D. G., Zavos C., & Kountouras J. (2011).  Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis.. Metabolism. 60(3), 313-26.
Polyzos, S. A., Kountouras J., & Zavos C. (2009).  Insulin resistance and therapy: cross-talk between phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways.. Med Hypotheses. 72(5), 610.
Polyzos, S. A., & Kountouras J. (2013).  Serum alpha-fetoprotein in patients with nonalcoholic fatty liver disease.. Eur Rev Med Pharmacol Sci. 17(17), 2411-2.
Polyzos, N. P., Fatemi H. M., Zavos A., Grimbizis G., Kyrou D., Velasco J-G., et al. (2011).  Aromatase inhibitors in post-menopausal endometriosis.. Reprod Biol Endocrinol. 9, 90.
Polyzos, S. A., Kountouras J., Papatheodorou A., Katsiki E., Patsiaoura K., Zafeiriadou E., et al. (2013).  Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.. Ann Hepatol. 12(5), 749-57.
Polyzos, S. A., & Anastasilakis A. D. (2016).  Periostin on the road to nonalcoholic fatty liver disease.. Endocrine. 51(1), 4-6.
Polyzos, S. Alexandros, Kountouras J., & Zavos C. (2010).  Nonlinear distribution of adiponectin in patients with nonalcoholic fatty liver disease limits its use in linear regression analysis.. J Clin Gastroenterol. 44(3), 229-30; author reply 230-1.
Polyzos, S. A., Perakakis N., & Mantzoros C. S. (2019).  Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement.. Metabolism. 96, 66-82.
Polyzos, S. A., & Kountouras J. (2019).  Helicobacter pylori infection and nonalcoholic fatty liver disease: Time for large clinical trials evaluating eradication therapy.. Helicobacter. 24(3), e12588.
Polyzos, S. A., Slavakis A., Koumerkeridis G., Katsinelos P., & Kountouras J. (2019).  Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort.. Horm Metab Res. 51(2), 134-140.
Polyzos, S. A., & Mantzoros C. S. (2015).  Leptin in health and disease: facts and expectations at its twentieth anniversary.. Metabolism. 64(1), 5-12.
Polyzos, S. A., Frühbeck G., & Kiortsis D. N. (2023).  Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease.. Curr Pharm Des. 29(41), 3263-3265.
Polyzos, S. A., Kita M., Efstathiadou Z., Goulis D. G., Benos A., Flaris N., et al. (2009).  The use of demographic, ultrasonographic and scintigraphic data in the diagnostic approach of thyroid nodules.. Exp Clin Endocrinol Diabetes. 117(4), 159-64.
Polyzos, S. A., Kountouras J., Polymerou V., Papadimitriou K. G., Zavos C., & Katsinelos P. (2016).   Vaspin, resistin, retinol-binding protein-4, interleukin-1α and interleukin-6 in patients with nonalcoholic fatty liver disease.. Ann Hepatol. 15(5), 705-14.
Polyzos, S. A., & Mantzoros C. S. (2024).  Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management.. Metabolism. 155936.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.